A Phase 1b Study of Oral Chk1 Inhibitor LY2880070 as Monotherapy in Patients with Advanced or Metastatic Cancer

Authors: Miller Jr WH, Chu Q, Bouganim N, Jonker D, Batist G, Buhlaiga N, Lheureux S, Spratlin J, Alcindor T, Smith P, Owen J, Zaknoen S, Stille JR, Fortier C, Vincett D, Oza A, Ozaki C
Publication: ASCO
Keywords: Cognigen, maximum tolerated dose, metastatic cancer, monotherapy, pharmacokinetics, poor metabolizer
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Background

In the context of DNA damage, Checkpoint Kinase 1 (Chk1) mediates a checkpoint response which arrests the cell cycle and allows the cell to complete DNA repair and replication. LY2880070(LY) is a selective adenosine triphosphate-competitive inhibitor of Chk1. Chk1 overexpression has been found in a variety of cancers. The safety of patients who are CYP2D6 poor metabolizers is an important consideration.

By Wilson H. Miller, Jr., Quincy Chu, Nathaniel Bouganim, Derek Jonker, Gerald Batist, Najwa Buhlaiga, Stephanie Lehureux, Jennifer Spratlin, Thierry Alcindor, Patricia S. Smith, Joel Owen, Sara Zaknoen, John R. Stille, Caroline Fortier, Darcy Vincett and Amit Oza presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting; May 29-31 2020; Virtual.